WHAT IS CLAIMED IS:

~~1. A transgene construct encoding a chimeric Igα subunit of the BCR, said chimeric Igα subunit comprising:~~

~~(a) an intracellular domain sequence and a transmembrane domain sequence of a non-human, Igα polypeptide sequence; and,~~

~~(b) a polypeptide having at least 85% sequence identity to the extracellular domain of human Igα of SEQ ID NO.: 1.~~

~~2. A transgene construct encoding a chimeric Igβ subunit of the BCR, said chimeric Igβ subunit comprising:~~

~~(a) an intracellular domain sequence and a transmembrane domain sequence of a non-human, Igβ subunit, and,~~

~~(b0 a polypeptide having at least 85% sequence identity to the extracellular domain of the human Igβ of SEQ ID NO.:7.~~

~~3. The transgene constructs of Claim 1, wherein said non-human Igα polypeptide sequence includes bovine (SEQ ID NO: 2); murine (SEQ ID NO: 3); canine (SEQ ID NO: 4); primate ((SEQ ID NO: 5); rabbit (SEQ ID NO: 6) or other non-human sequences.~~

~~4. The transgene constructs of Claim 2, wherein said non-human Igβ polypeptide sequence includes canine (SEQ ID NO: 8); rat (SEQ ID NO: 9); bovine (SEQ ID NO: 10); murine (SEQ ID NO: 11); chicken (SEQ ID NO: 12); or other non-human sequences.~~

~~5~~1. A non-human transgenic animal comprising:

(a) a transgene construct encoding ~~either~~ a full-length, human Igα subunit of SEQ ID NO.: 1 ~~or the chimeric Igα subunit of claim 1~~; and~~/or~~,

(b) a transgene construct encoding either a full-length, human Igβ subunit of SEQ ID NO.: 7 ~~or the chimeric Igβ subunit of claim 2~~; and,

(c) a transgene construct encoding a human(ized) immunoglobulin locus;

wherein the resultant transgene products combine to form a human(ized) B-cell receptor complex.

62. The non-human transgenic animal of claim ~~5~~ 1 wherein the expression of any endogenous Ig production and/or Igα and/or Igβ subunits of the non-human transgenic animal has been substantially reduced.

73. The non-human transgenic animal of claim ~~5~~ 1 wherein said animal is selected from a group consisting of rabbit, mouse, rat, pig, sheep, goat, bird, horse, donkey and cow.

84. The non-human transgenic animal of claim ~~5~~ 1 which is a rabbit.

~~9. An isolated human(ized) immunoglobulin from the non-human transgenic animal of claim 5, wherein said human(ized) immunoglobulin is either an antibody or an antibody fragment.~~

~~10. The isolated human(ized) immunoglobulin of claim 9, wherein said antibody is a polyclonal or a monoclonal antibody.~~

~~11. The isolated human(ized) immunoglobulin of claim 9, wherein said antibody fragment is a fragment of a polyclonal or a monoclonal antibody.~~

~~12. The isolated human(ized) immunoglobulin of claim 9, wherein said antibody or antibody fragment is labeled.~~

~~13. The isolated human(ized) immunoglobulin of claim 9, wherein said antibody or antibody fragment is fused to a toxin to form an immunotoxin or is coupled to a therapeutic agent.~~

~~14. The isolated human(ized) immunoglobulin of claim 9, wherein said antibody or antibody fragment is fused to a heterologous amino acid sequence.~~

~~15. The isolated human(ized) immunoglobulin of claim 11, wherein said antibody fragment is an Fc, Fv, Fab, Fab' or F(ab') 2 fragment.~~

~~16~~5. An isolated B-cell from said non-human transgenic animal of claim ~~5~~1, wherein said B-cell expresses ~~either~~ the native human Igα subunit ~~or a chimeric Igα subunit~~ and/~~or~~ ~~either~~ the native human Igβ subunit ~~or the chimeric Igβ subunit~~, and the human(ized) immunoglobulin locus.

~~17~~6. The isolated B-cell of Claim ~~16~~ 5 wherein said B-cell is immortalized.

~~18~~7. The isolated B-cell of Claim ~~16~~ 5 or ~~17~~ 6 wherein said B-cell is derived from a rabbit.

~~19. An antibody preparation comprising the antibody or the antibody fragment of claim 9.~~

~~20. A pharmaceutical composition comprising the antibody preparation of Claim 19 in a mixture with a pharmaceutically acceptable ingredient.~~

~~21. The pharmaceutical composition of claim 20 comprising a monoclonal antibody or a fragment thereof.~~

~~22. The pharmaceutical composition of claim 20 comprising one or a plurality of polyclonal antibodies or fragments thereof.~~